And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather modest. We hope to catch up on our reading, hang with a short person or two, and promenade with the official mascot. And what about you? This is a fine time to enjoy the great outdoors. You could arrange for a mail-in ballot for the upcoming election. Or you could reach out to someone feeling isolated these days. Well, whatever you do, have a grand time. But be safe — wear a mask. Enjoy, and see you soon. …

Roche (RHHBY) reported that its Actemra drug reduces the likelihood patients with Covid-19-related pneumonia need mechanical ventilation, Pharmaphorum reports. Hospitalized patients taking the drug were 44% less likely to need ventilators or die, citing the results of a Phase 3 study, which is the first global Phase 3 Covid-19 clinical trial to primarily enroll patients from underrepresented racial and ethnic groups. There was no statistically significant improvement in reducing mortality alone, however.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy